Phibro Animal Health Corporation partners with MJ Biologics to combat PRRSV

Phibro Animal Health Corporation (PAHC) and MJ Biologics have successfully collaborated to produce a USDA licensed autogenous  that can help swine producers tackle the complex PRRSV disease problem.

MJPRRS® Viral Antigen Concentrate Vaccine Technology and MJPRRS® Grouping Technology are combined with MVP Technologies' proprietary EMULSIGEN®-D adjuvant to produce the 4th generation MJPRRS® Vaccine. This specialopswatch.es vaccine contains unique PRRS viral antigens in the presence of MVP Technologies’ adjuvant.

The two companies have scaled-up and optimized the unique MJPRRS® vaccine technology in PAHC’s new virus production facility in Omaha, NE. MJPRRS® vaccines produced by PAHC must pass stringent quality control testing prior to release to assure the targeted levels of antigenic mass. PAHC is able to produce the exclusive autogenous vaccine in various serial sizes up to 100,000 doses.

MVP Laboratories teams up with Dr. Susan Detmer to spread swine influenza awareness

In an effort to keep our clients aware of the latest developments, MVP Laboratories is working with Dr. Susan Detmer of the University of Minnesota to publish an informative newsletter entitled Flu News. It deals with SIV as well as the current H1N1 pandemic and its implications for both humans and swine.

Susan Detmer received her doctor of veterinary medicine at the University of Minnesota, College of Veterinary Medicine in St. Paul, MN in 2003. In 2006, Susan began her combined PhD/residency training in anatomic pathology at the University of Minnesota. Her field of research is in control and characterization of swine influenza viruses, in particular the molecular epidemiology of swine influenza viruses of perceived high virulence. She is currently working with the Minnesota Center for Excellence for Influenza Research & Surveillance (MCEIRS) under her research advisors, Drs. Marie Gramer and Sagar Goyal.

View issues of Flu News.

MVP Laboratories provides relief for Mhs-related lameness

Dr. Boh Chang Lin, Director of R&D, has optimized a culturing method for Mycoplasma hyosynoviae (Mhs) that supports growth to the level of CFU's needed to produce high antigen content vaccines. This development is a significant breakthrough that offers a better tool for the control of Mhs-related lameness using licensed autogenous vaccines and has led to the filing of a patent application*. As depicted below, strains of Mhs recently isolated at MVP's diagnostic laboratory varied considerably based on soluble protein profile results. Discrimination of Mhs isolates by means of this analysis can greatly assist practitioners in the selection of candidates to use in a Tailor-made® licensed autogenous vaccine.

Here is a dendrogram showing similarity (%) between five M. hyosynoviae field strains:


National Hog Farmer: Getting to the Bottom of Lameness Concerns
National Hog Farmer: A Closer Look at Mycoplasma-Related Lameness
Is Lameness from Mycoplasma Infection Hobbling Your Profits?

*Patent Pending